Evidence map›Paper›PMID 42665562›Full record

ArticleChemMedChem2026

Piperazine and Morpholine Protoporphyrin IX Derivatives Intensify Biomolecules Oxidation and Phototoxicity in Triple-Negative Breast Cancer.

Maynne Duarte Suriani Franco, Thibault Joseph William Jacques Dit Lapierre, Tarcisio Paiva Mendonça, Luiz Felipe Fernandes Peixoto, Renata Roland Teixeira, Joyce Ferreira Da Costa Guerra, Kelly Aparecida Geraldo Yoneyama Tudini, Daniele Lisboa Ribeiro, Foued Salmen Espindola, Allisson Benetti Justino and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maynne Duarte Suriani FrancoInstitute of Chemistry, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.ORCID https://orcid.org/0009-0006-1392-1433
Thibault Joseph William Jacques Dit LapierreInstitute of Chemistry, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-2347-9515
Tarcisio Paiva MendonçaInstitute of Biotechnology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Luiz Felipe Fernandes PeixotoInstitute of Biomedical Sciences, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-9896-5550
Renata Roland TeixeiraInstitute of Biotechnology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Joyce Ferreira Da Costa GuerraInstitute of Biotechnology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Kelly Aparecida Geraldo Yoneyama TudiniInstitute of Biotechnology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0003-0329-5521
Daniele Lisboa RibeiroInstitute of Biomedical Sciences, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Foued Salmen EspindolaInstitute of Biotechnology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-6937-1411
Allisson Benetti JustinoInstitute of Biotechnology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0003-3616-6611
Celso de Oliveira Rezende JúniorInstitute of Chemistry, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Tayana Mazin TsuboneInstitute of Chemistry, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0003-4795-4568

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 300079/2025-7Conselho Nacional de Desenvolvimento Científico e Tecnológico 303853/2025-5Conselho Nacional de Desenvolvimento Científico e Tecnológico 308094/2025-5Conselho Nacional de Desenvolvimento Científico e Tecnológico 407282/2023-8Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Coordenação de Aperfeiçoamento de Pessoal de Nível Superior PROEXFundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-00864-25Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-02185-24Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-02393-24Fundação de Amparo à Pesquisa do Estado de Minas Gerais APQ-02533-23Fundação de Amparo à Pesquisa do Estado de Minas Gerais RED-00110-23
6 · The paper itself

Abstract

Photodynamic therapy (PDT) is a clinically established approach that relies on the localized generation of reactive oxygen species (ROS) mediated by a photosensitizer (PS), light, and molecular oxygen. Protoporphyrin IX (PpIX) is an approved PS; however, its intracellular retention is limited, factor that can alter its overall photodynamic efficiency. In this study, we report how the design of PpIX derivatives bearing piperazine (PpIX-Pip) or morpholine (PpIX-Morp) substituents may modulate lipophilicity, cellular uptake, oxidative stress, and phototoxicity. The photodynamic activity of these derivatives was evaluated in the aggressive triple-negative human breast cancer cell line MDA-MB-231. Both derivatives showed greater time-dependent cellular retention and enhanced photodynamic activity compared to PpIX, promoting oxidative stress, and triggering loss of mitochondrial membrane potential and caspase-3 activation. These results highlight the impact of rational structural modification of PpIX on photodynamic efficiency and provide valuable structure-activity relationship insights for the development of improved porphyrin-based PS for PDT.

Indexed as

Antineoplastic AgentsPhotosensitizing AgentsPiperazinePiperazinesProtoporphyrinsTriple Negative Breast NeoplasmsCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorFemaleHumansMDA-MB-231 CellsMembrane Potential, MitochondrialMolecular StructureMorpholinesOxidation-ReductionAntineoplastic AgentsmorpholineMorpholinesPhotosensitizing AgentsPiperazinePiperazinesprotoporphyrin IXProtoporphyrinsReactive Oxygen Speciesbreast cancermorpholinephotodynamic activitypiperazineprotoporphyrin IX

Identifiers

PMID42665562
PMCPMC13524843

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.